Pediatric pharmacogenetics: profiling CYP2C8 polymorphisms at King Abdulaziz University Dental Clinic.

Q2 Pharmacology, Toxicology and Pharmaceutics
Amina M Bagher, Rania A Aboud, Noura M Alkinaidri, Saja A Aljilani, Rawan H Hareeri, Lenah S Binmahfouz, Sara M Bagher
{"title":"Pediatric pharmacogenetics: profiling CYP2C8 polymorphisms at King Abdulaziz University Dental Clinic.","authors":"Amina M Bagher, Rania A Aboud, Noura M Alkinaidri, Saja A Aljilani, Rawan H Hareeri, Lenah S Binmahfouz, Sara M Bagher","doi":"10.1515/dmpt-2024-0015","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Ibuprofen, a widely used non-steroidal anti-inflammatory (NSAID) for managing pain and inflammation in pediatric patients, is metabolized by the CYP2C8 enzyme. Studies suggest that the <i>CYP2C8*2</i>, <i>*3</i>, and <i>*4</i> variations of the <i>CYP2C8</i> gene diminish ibuprofen metabolism, increasing the risk of adverse reactions. The aim of this study was to determine the frequency of the <i>CYP2C8*2</i>, <i>*3</i>, and <i>*4</i> alleles and genotypes in a pediatric population attending the King Abdulaziz University dental clinic and compare our findings to those of other populations.</p><p><strong>Methods: </strong>A cross-sectional study was conducted with 140 healthy Saudi children ages 6-12. Saliva samples were collected using Oragene™ DNA Sample Collection Kits and analyzed for polymorphisms using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).</p><p><strong>Results: </strong>The study identified that <i>CYP2C8*2</i> AA, AT, and TT genotypes occurred at frequencies of 87.86 %, 9.29 %, and 2.86 %, respectively. For <i>CYP2C8*3</i>, AA, AG, and GG genotypes were found in 87.14 , 8.75, and 4.29 % of subjects, respectively. The <i>CYP2C8*4</i> allele was less frequent, with CC and CG genotypes at 97.86 % and 2.14 %, respectively, and the GG genotype was absent. Allele frequencies for <i>CYP2C8*2</i>, <i>*3</i>, and <i>*4</i> were 7.5 %, 8.57 %, and 1.07 %, respectively.</p><p><strong>Conclusions: </strong>Our findings reveal that the allelic frequencies for the <i>CYP2C8</i> polymorphisms in the Saudi pediatric cohort are substantially elevated compared to those reported in other Asian populations. This suggests Saudis may experience more varied drug responses, especially for medications that undergo metabolism by the CYP2C8 enzyme, like ibuprofen.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2024-0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Ibuprofen, a widely used non-steroidal anti-inflammatory (NSAID) for managing pain and inflammation in pediatric patients, is metabolized by the CYP2C8 enzyme. Studies suggest that the CYP2C8*2, *3, and *4 variations of the CYP2C8 gene diminish ibuprofen metabolism, increasing the risk of adverse reactions. The aim of this study was to determine the frequency of the CYP2C8*2, *3, and *4 alleles and genotypes in a pediatric population attending the King Abdulaziz University dental clinic and compare our findings to those of other populations.

Methods: A cross-sectional study was conducted with 140 healthy Saudi children ages 6-12. Saliva samples were collected using Oragene™ DNA Sample Collection Kits and analyzed for polymorphisms using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Results: The study identified that CYP2C8*2 AA, AT, and TT genotypes occurred at frequencies of 87.86 %, 9.29 %, and 2.86 %, respectively. For CYP2C8*3, AA, AG, and GG genotypes were found in 87.14 , 8.75, and 4.29 % of subjects, respectively. The CYP2C8*4 allele was less frequent, with CC and CG genotypes at 97.86 % and 2.14 %, respectively, and the GG genotype was absent. Allele frequencies for CYP2C8*2, *3, and *4 were 7.5 %, 8.57 %, and 1.07 %, respectively.

Conclusions: Our findings reveal that the allelic frequencies for the CYP2C8 polymorphisms in the Saudi pediatric cohort are substantially elevated compared to those reported in other Asian populations. This suggests Saudis may experience more varied drug responses, especially for medications that undergo metabolism by the CYP2C8 enzyme, like ibuprofen.

儿科药物遗传学:阿卜杜勒-阿齐兹国王大学牙科诊所的 CYP2C8 多态性分析。
研究目的布洛芬是一种广泛用于治疗儿科患者疼痛和炎症的非甾体抗炎药(NSAID),它通过 CYP2C8 酶进行代谢。研究表明,CYP2C8基因的CYP2C8*2、*3和*4变异会降低布洛芬的代谢,增加不良反应的风险。本研究旨在确定在阿卜杜勒阿齐兹国王大学牙科诊所就诊的儿科人群中 CYP2C8*2、*3 和 *4 等位基因和基因型的频率,并将我们的研究结果与其他人群的结果进行比较:对 140 名 6-12 岁的健康沙特儿童进行了横断面研究。使用 Oragene™ DNA 样品采集试剂盒采集唾液样本,并使用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)分析多态性:研究发现,CYP2C8*2 AA、AT 和 TT 基因型的出现频率分别为 87.86 %、9.29 % 和 2.86 %。在 CYP2C8*3 中,发现 AA、AG 和 GG 基因型的受试者分别占 87.14%、8.75% 和 4.29%。CYP2C8*4 等位基因的频率较低,CC 和 CG 基因型分别占 97.86 % 和 2.14 %,没有 GG 基因型。CYP2C8*2、*3和*4的等位基因频率分别为7.5 %、8.57 %和1.07 %:我们的研究结果表明,与其他亚洲人群相比,沙特儿科人群中 CYP2C8 多态性的等位基因频率大幅升高。这表明沙特人可能会对药物产生更多不同的反应,尤其是对布洛芬等通过CYP2C8酶代谢的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug metabolism and personalized therapy
Drug metabolism and personalized therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
2.30
自引率
0.00%
发文量
35
期刊介绍: Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信